793 related articles for article (PubMed ID: 29087303)
21. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
22. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
[TBL] [Abstract][Full Text] [Related]
23. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
24. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma.
Bennett JA; Safdar N; Segal JP; Lastra RR; Oliva E
Int J Gynecol Pathol; 2021 Mar; 40(2):156-164. PubMed ID: 32897960
[TBL] [Abstract][Full Text] [Related]
25. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
Reichl KD; Lee ECY; Gopalsamy A
Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
[TBL] [Abstract][Full Text] [Related]
26. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
27. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
28. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
Nguyen VT; Tessema M; Weissman BE
Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
[TBL] [Abstract][Full Text] [Related]
29. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic Therapy for Epithelioid Sarcoma.
Rothbart SB; Baylin SB
Cell; 2020 Apr; 181(2):211. PubMed ID: 32302562
[TBL] [Abstract][Full Text] [Related]
31. SWI/SNF protein and claudin-4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum.
Chaudet K; Kem M; Lerwill M; Young RH; Mino-Kenudson M; Agaimy A; McCluggage WG; Oliva E
Histopathology; 2020 Aug; 77(2):231-239. PubMed ID: 32268438
[TBL] [Abstract][Full Text] [Related]
32. SWI/SNF Alterations in Squamous Bladder Cancers.
Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma.
Zhang Z; Li Q; Sun S; Li Z; Cui ZG; Zhang M; Liu Q; Zhang Y; Xiong S; Zhang S
World J Surg Oncol; 2022 Dec; 20(1):383. PubMed ID: 36464671
[TBL] [Abstract][Full Text] [Related]
34. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
35. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
[TBL] [Abstract][Full Text] [Related]
36. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
37. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
38. Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.
Agaimy A; Bertz S; Cheng L; Hes O; Junker K; Keck B; Lopez-Beltran A; Stöckle M; Wullich B; Hartmann A
Virchows Arch; 2016 Sep; 469(3):321-30. PubMed ID: 27339451
[TBL] [Abstract][Full Text] [Related]
39. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
40. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
